Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Mirte Scherpenisse"'
Autor:
Mirte Scherpenisse, Neeltje A. Kootstra, Margreet Bakker, Ben Berkhout, Alexander O. Pasternak
Publikováno v:
mBio, Vol 12, Iss 2 (2021)
Human immunodeficiency virus (HIV) infection is currently managed by antiretroviral drugs, which block virus replication and promote immune restoration. However, the latter effect is not universal, with a proportion of infected individuals failing to
Externí odkaz:
https://doaj.org/article/32dcdb13ffcc495e9446aa3ff1e69aa0
Autor:
Henrike J Vriend, Johannes A Bogaards, Fiona R M van der Klis, Mirte Scherpenisse, Hein J Boot, Audrey J King, Marianne A B van der Sande, Medical Microbiological Laboratories, Municipal Health Services
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e60696 (2013)
BackgroundTo monitor the impact of human papillomavirus types 16 and 18 vaccine on HPV infection dynamics in the Netherlands, we started an ongoing study in sexually transmitted infection (STI) clinics in 2009. Here, we analyze baseline type-specific
Externí odkaz:
https://doaj.org/article/e8fae27f8a554fc98aaac28b7aeb0e73
Autor:
Mirte Scherpenisse, Rutger M Schepp, Madelief Mollers, Chris J L M Meijer, Guy A M Berbers, Fiona R M van der Klis
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e74797 (2013)
OBJECTIVES: In order to assess HPV-specific IgG characteristics, we evaluated multiple aspects of the humoral antibody response that will provide insight in the HPV humoral immune response induced by HPV infection and vaccination. METHODS: Cross-reac
Externí odkaz:
https://doaj.org/article/4c6ef73f7984467188acdf56a277871e
Autor:
Mirte Scherpenisse, Madelief Mollers, Rutger M Schepp, Hein J Boot, Chris J L M Meijer, Guy A M Berbers, Fiona R M van der Klis, Hester E de Melker
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e48807 (2012)
OBJECTIVE: This study evaluates trends in antibody seroprevalences of seven high-risk human papillomavirus (hr-HPV) serotypes (HPV16, 18, 31, 33, 45, 52, and 58) between the 1995-96 and 2006-07 sero-surveys among the Dutch general population in the p
Externí odkaz:
https://doaj.org/article/5fe9efb755874b5cbf45adabfb3205a6
Autor:
Alexander O. Pasternak, Ben Berkhout, Neeltje A. Kootstra, Mirte Scherpenisse, Margreet Bakker
Publikováno v:
mBio, 12(2):e00099-21, 1-25. American Society for Microbiology
mBio, Vol 12, Iss 2 (2021)
mBio
mBio, Vol 12, Iss 2 (2021)
mBio
Human immunodeficiency virus (HIV) infection is currently managed by antiretroviral drugs, which block virus replication and promote immune restoration. However, the latter effect is not universal, with a proportion of infected individuals failing to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a91046dc4350a988f8178786c7acdd33
https://pure.amc.nl/en/publications/cellassociated-hiv1-unsplicedtomultiplyspliced-rna-ratio-at-12-weeks-of-art-predicts-immune-reconstitution-on-therapy(efe3b063-5f73-48c8-aa96-54c51a283ce4).html
https://pure.amc.nl/en/publications/cellassociated-hiv1-unsplicedtomultiplyspliced-rna-ratio-at-12-weeks-of-art-predicts-immune-reconstitution-on-therapy(efe3b063-5f73-48c8-aa96-54c51a283ce4).html
Autor:
Hester E. de Melker, Fiona R. M. van der Klis, Mirjam J. Knol, Audrey J. King, Madelief Mollers, Chris J.L.M. Meijer, Mirte Scherpenisse
Publikováno v:
Vaccine, 33(23), 2678-2683. Elsevier BV
Mollers, M, King, A J, Knol, M J, Scherpenisse, M, Meijer, C J L M, van der Klis, F R M & de Melker, H E 2015, ' Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study ', Vaccine, vol. 33, no. 23, pp. 2678-2683 . https://doi.org/10.1016/j.vaccine.2015.04.016
Mollers, M, King, A J, Knol, M J, Scherpenisse, M, Meijer, C J L M, van der Klis, F R M & de Melker, H E 2015, ' Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study ', Vaccine, vol. 33, no. 23, pp. 2678-2683 . https://doi.org/10.1016/j.vaccine.2015.04.016
Introduction Because of the long interval between infection with high-risk human papillomavirus (hrHPV) and development of cervical cancer surrogate markers for cancer incidence are necessary to monitor vaccine effectiveness (VE). The aim of this stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98a269e234b317265a3688a3bc6709fa
https://doi.org/10.1016/j.vaccine.2015.04.016
https://doi.org/10.1016/j.vaccine.2015.04.016
Autor:
Fiona R. M. van der Klis, Hester E. de Melker, Mirte Scherpenisse, Chris J.L.M. Meijer, Jeanique M. Vossen, Madelief Mollers
Publikováno v:
Journal of Medical Virology. 85:1379-1385
In 2006/2007, two vaccines were licensed against two of the most common HPV types that cause about 70% of cervical cancers. Clinical trials show that vaccinated individuals develop high levels of neutralizing antibodies. Although these data suggest t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::482216871670ace5eb0a37a924654ac8
https://doi.org/10.1002/jmv.23616
https://doi.org/10.1002/jmv.23616
Autor:
Guy A. M. Berbers, Rutger M. Schepp, Hester E. de Melker, Hein J. Boot, Fiona R. M. van der Klis, Madelief Mollers, Chris J.L.M. Meijer, Mirte Scherpenisse
Publikováno v:
Vaccine, 30(47), 6686-6693. Elsevier BV
Scherpenisse, M, Mollers, M, Schepp, R M, Boot, H J, de Melker, H E, Meijer, C J L M, Berbers, G A M & van der Klis, F R M 2012, ' Seroprevalence of seven high-risk HPV types in The Netherlands ', Vaccine, vol. 30, no. 47, pp. 6686-6693 . https://doi.org/10.1016/j.vaccine.2012.08.068
Scherpenisse, M, Mollers, M, Schepp, R M, Boot, H J, de Melker, H E, Meijer, C J L M, Berbers, G A M & van der Klis, F R M 2012, ' Seroprevalence of seven high-risk HPV types in The Netherlands ', Vaccine, vol. 30, no. 47, pp. 6686-6693 . https://doi.org/10.1016/j.vaccine.2012.08.068
Background To obtain insight into the age-specific seroprevalence for seven high-risk human papillomavirus (hr-HPV) serotypes (HPV16, 18, 31, 33, 45, 52, and 58) among the general population in the pre-vaccination era in The Netherlands. Methods From
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee0afd85b3d794dfaaa23071a9b400cf
https://doi.org/10.1016/j.vaccine.2012.08.068
https://doi.org/10.1016/j.vaccine.2012.08.068
Autor:
Carline Tacke, Marloes W Heijstek, Nico M Wulffraat, Rutger M. Schepp, Noortje Groot, Mirte Scherpenisse, Guy A. M. Berbers, Anne-Marie Buisman, Fiona R. M. van der Klis
Publikováno v:
Annals of the Rheumatic Diseases, 73(8), 1500-1507. BMJ Publishing Group
Heijstek, M W, Scherpenisse, M, Groot, N, Tacke, C, Schepp, R M, Buisman, A M, Berbers, G A M, van der Klis, F R M & Wulffraat, N M 2014, ' Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study ', Annals of the Rheumatic Diseases, vol. 73, no. 8, pp. 1500-1507 . https://doi.org/10.1136/annrheumdis-2013-203429
Heijstek, M W, Scherpenisse, M, Groot, N, Tacke, C, Schepp, R M, Buisman, A M, Berbers, G A M, van der Klis, F R M & Wulffraat, N M 2014, ' Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study ', Annals of the Rheumatic Diseases, vol. 73, no. 8, pp. 1500-1507 . https://doi.org/10.1136/annrheumdis-2013-203429
Objectives To compare the immunogenicity and safety of the bivalent human papillomavirus (HPV)16/18 vaccine between female patients with juvenile idiopathic arthritis (JIA) and healthy female adolescents. Methods 68 patients and 55 healthy girls aged
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5664a149a85c8168b0b1dc65215fb92d
https://research.vumc.nl/en/publications/e40c2fb6-758a-4f86-9811-30a2d42774d0
https://research.vumc.nl/en/publications/e40c2fb6-758a-4f86-9811-30a2d42774d0
Autor:
Madelief, Mollers, Jeanique M, Vossen, Mirte, Scherpenisse, Fiona R M, van der Klis, Chris J L M, Meijer, Hester E, de Melker
Publikováno v:
Journal of medical virology. 85(8)
In 2006/2007, two vaccines were licensed against two of the most common HPV types that cause about 70% of cervical cancers. Clinical trials show that vaccinated individuals develop high levels of neutralizing antibodies. Although these data suggest t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::833853ba06f8d78a0c719e3c0a66c83c
https://pubmed.ncbi.nlm.nih.gov/23722396
https://pubmed.ncbi.nlm.nih.gov/23722396